Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) · earnings preview
Quarter
Q3
EPS estimate to actual
$0.94
Revenue estimate to actual
$79.7M
At a glance
Key takeaways
01Rigel Pharmaceuticals will report Q3 2026 earnings on November 3, 2026 after market close with expected EPS of $0.94 versus $0.00 in Q3 2025.
02Expected Q3 revenue is $79.7M, representing year-over-year growth from the prior year period.
03The stock trades at $50.51 with a market cap of $751.7M as of the article date.
04Recent earnings history shows significant volatility, with Q2 2026 beating estimates by 417.6% but Q1 2026 missing by 48.2%.
05Investors should evaluate Q3 results alongside revenue growth, margin trends, and forward guidance rather than focusing solely on EPS.
Earnings Results
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is scheduled to report its Q3 earnings results on November 03, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $0.94, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $79.7M, up from a year ago.
Company Overview
The stock currently trades at $50.51 with a market capitalization of $751.7M.
Ahead of Rigel Pharmaceuticals, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Rigel Pharmaceuticals, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.